Importance Randomized clinical trials have shown that glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) cause significant weight loss and reduce cardiovascular events in …

Prevalence of type 2 diabetes increased from 2.5% of the US population in 1990 to 10.5% in
2018. This creates a major public health problem, due to increases in long-term …

Prediabetes is the first stage of a continuum that extends through the diagnosis of clinical
type 2 diabetes towards long-standing diabetes with multiple comorbidities. The diagnosis of …

Type 2 diabetes (T2D), which accounts for 90% to 95% of all cases of diabetes, is on the rise
and is expected to affect 700 million people globally by 2045. 1 People with T2D have …

Objective To report on the use of antihyperglycemic agents (AHAs) by age (ie< 65,≥ 65
years) in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD) or …

Background Newer diabetes medications have cardiorenal benefits beyond blood sugar
lowering that make them a preferred treatment option in many patients. Despite this, studies …

Background Use of sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) falls short
of their cardiorenal protective benefits. Patient and provider-level barriers hinder the …

Cardiovascular (CV) disease continues to be the leading cause of death and disability
across the globe and is especially burdensome on patients with diabetes mellitus (DM)[1] …

Background: Heart failure (HF) is an important adverse outcome of diabetes mellitus (DM)
with high rates of mortality and HF-related hospitalizations. The risk of HF is 2 times higher in …

Objective With the increasing burden of heart failure (HF) in the Middle East Region and
Africa (MEA), it is imperative to shift the focus to prevention and early detection of …